Senti Bio reports FY2023 net loss of $71.1M; cash runway into Q1 2025; IND cleared for SENTI-202 AML therapy

Senti Biosciences, Inc.

Net loss for FY2023 was $71.1M ($1.60/share) vs $58.2M in FY2022.
Cash, cash equivalents and short-term investments of $35.9M at 12/31/2023; plus $18.9M GeneFab receivable to fund into Q1 2025.
R&D expenses $32.2M (FY2023), G&A $37.2M; net loss includes $12.3M gain from discontinued operations and $25.7M impairment.
FDA cleared IND for SENTI-202 (logic-gated CAR-NK for AML); first patient dosing expected Q2 2024, initial efficacy data by year-end 2024.
Collaboration with Celest for SENTI-301A (HCC) in China; first patient dosing expected Q2 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Senti Biosciences, Inc. reported the year ended December 31, 2023 results: net income Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended December 31, 2023. Net loss for, EPS $0.42 per basic and diluted share (quarter) and $1.60 per share (year).

Period: the year ended December 31, 2023
Net income: Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended December 31, 2023. Net loss for
EPS: $0.42 per basic and diluted share (quarter) and $1.60 per share (year)
Result: reported results

Exact text from the filing

On March 21, 2024, Senti Biosciences, Inc. issued a press release announcing its financial results for the year ended December 31, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001854270-24-000027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.